197 related articles for article (PubMed ID: 16390818)
41. Reversible increase in tight junction permeability to macromolecules in rat ileal mucosa in vitro by sodium caprate, a constituent of milk fat.
Söderholm JD; Oman H; Blomquist L; Veen J; Lindmark T; Olaison G
Dig Dis Sci; 1998 Jul; 43(7):1547-52. PubMed ID: 9690393
[TBL] [Abstract][Full Text] [Related]
42. A permeation enhancer for increasing transport of therapeutic macromolecules across the intestine.
Gupta V; Hwang BH; Doshi N; Mitragotri S
J Control Release; 2013 Dec; 172(2):541-9. PubMed ID: 23680288
[TBL] [Abstract][Full Text] [Related]
43. Absorption study of deoxycholic acid-heparin conjugate as a new form of oral anti-coagulant.
Kim SK; Lee DY; Lee E; Lee YK; Kim CY; Moon HT; Byun Y
J Control Release; 2007 Jul; 120(1-2):4-10. PubMed ID: 17490773
[TBL] [Abstract][Full Text] [Related]
44. Restoration of rat colonic epithelium after in situ intestinal instillation of the absorption promoter, sodium caprate.
Wang X; Maher S; Brayden DJ
Ther Deliv; 2010 Jul; 1(1):75-82. PubMed ID: 22816121
[TBL] [Abstract][Full Text] [Related]
45. Development and in vivo evaluation of an oral delivery system for low molecular weight heparin based on thiolated polycarbophil.
Kast CE; Guggi D; Langoth N; Bernkop-Schnürch A
Pharm Res; 2003 Jun; 20(6):931-6. PubMed ID: 12817900
[TBL] [Abstract][Full Text] [Related]
46. Oral characteristics of bergenin and the effect of absorption enhancers in situ, in vitro and in vivo.
Qin X; Yuan F; Zhou D; Huang Y
Arzneimittelforschung; 2010; 60(4):198-204. PubMed ID: 20486470
[TBL] [Abstract][Full Text] [Related]
47. Impact of Intestinal Concentration and Colloidal Structure on the Permeation-Enhancing Efficiency of Sodium Caprate in the Rat.
Berg S; Kärrberg L; Suljovic D; Seeliger F; Söderberg M; Perez-Alcazar M; Van Zuydam N; Abrahamsson B; Hugerth AM; Davies N; Bergström CAS
Mol Pharm; 2022 Jan; 19(1):200-212. PubMed ID: 34928160
[TBL] [Abstract][Full Text] [Related]
48. Amorphous solid dispersion of berberine with absorption enhancer demonstrates a remarkable hypoglycemic effect via improving its bioavailability.
Zhaojie M; Ming Z; Shengnan W; Xiaojia B; Hatch GM; Jingkai G; Li C
Int J Pharm; 2014 Jun; 467(1-2):50-9. PubMed ID: 24607213
[TBL] [Abstract][Full Text] [Related]
49. Assessment and modulation of acamprosate intestinal absorption: comparative studies using in situ, in vitro (CACO-2 cell monolayers) and in vivo models.
Zornoza T; Cano-Cebrián MJ; Nalda-Molina R; Guerri C; Granero L; Polache A
Eur J Pharm Sci; 2004 Aug; 22(5):347-56. PubMed ID: 15265504
[TBL] [Abstract][Full Text] [Related]
50. Bifunctional peptidomimetic prodrugs of didanosine for improved intestinal permeability and enhanced acidic stability: synthesis, transepithelial transport, chemical stability and pharmacokinetics.
Yan Z; Sun J; Chang Y; Liu Y; Fu Q; Xu Y; Sun Y; Pu X; Zhang Y; Jing Y; Yin S; Zhu M; Wang Y; He Z
Mol Pharm; 2011 Apr; 8(2):319-29. PubMed ID: 21280612
[TBL] [Abstract][Full Text] [Related]
51. Evaluation of intestinal absorption enhancement and local mucosal toxicity of two promoters. I. Studies in isolated rat and human colonic mucosae.
Maher S; Kennelly R; Bzik VA; Baird AW; Wang X; Winter D; Brayden DJ
Eur J Pharm Sci; 2009 Nov; 38(4):291-300. PubMed ID: 19737613
[TBL] [Abstract][Full Text] [Related]
52. Intestinal absorption of raltitrexed and evaluation of the effects of absorption enhancers.
Yu Y; Lu Y; Zhao X; Li X; Yin Z
Pharmazie; 2013 Sep; 68(9):732-43. PubMed ID: 24147341
[TBL] [Abstract][Full Text] [Related]
53. Oral heparin delivery: design and in vivo evaluation of a stomach-targeted mucoadhesive delivery system.
Schmitz T; Leitner VM; Bernkop-Schnürch A
J Pharm Sci; 2005 May; 94(5):966-73. PubMed ID: 15793802
[TBL] [Abstract][Full Text] [Related]
54. Nasal administration of low molecular weight heparin.
Arnold J; Ahsan F; Meezan E; Pillion DJ
J Pharm Sci; 2002 Jul; 91(7):1707-14. PubMed ID: 12115833
[TBL] [Abstract][Full Text] [Related]
55. Evaluation of the impact of multivalent metal ions on the permeation behavior of Dolutegravir sodium.
Grießinger JA; Hauptstein S; Laffleur F; Netsomboon K; Bernkop-Schnürch A
Drug Dev Ind Pharm; 2016; 42(7):1118-26. PubMed ID: 26552713
[TBL] [Abstract][Full Text] [Related]
56. Spray freeze drying with polyvinylpyrrolidone and sodium caprate for improved dissolution and oral bioavailability of oleanolic acid, a BCS Class IV compound.
Tong HH; Du Z; Wang GN; Chan HM; Chang Q; Lai LC; Chow AH; Zheng Y
Int J Pharm; 2011 Feb; 404(1-2):148-58. PubMed ID: 21094233
[TBL] [Abstract][Full Text] [Related]
57. Comparison of absorption-enhancing effect between sodium caprate and disodium ethylenediaminetetraacetate in Caco-2 cells.
Tomita M; Hayashi M; Awazu S
Biol Pharm Bull; 1994 May; 17(5):753-5. PubMed ID: 7920449
[TBL] [Abstract][Full Text] [Related]
58. In vitro interactions between the oral absorption promoter, sodium caprate (C(10)) and S. typhimurium in rat intestinal ileal mucosae.
Cox AB; Rawlinson LA; Baird AW; Bzik V; Brayden DJ
Pharm Res; 2008 Jan; 25(1):114-22. PubMed ID: 17546408
[TBL] [Abstract][Full Text] [Related]
59. Transepithelial electrical resistance is not a reliable measurement of the Caco-2 monolayer integrity in Transwell.
Mukherjee T; Squillantea E; Gillespieb M; Shao J
Drug Deliv; 2004; 11(1):11-8. PubMed ID: 15168786
[TBL] [Abstract][Full Text] [Related]
60. Evaluation in pig of an intestinal administration device for oral peptide delivery.
Berg S; Uggla T; Antonsson M; Nunes SF; Englund M; Rosengren L; Fahraj M; Wu X; Govender R; Söderberg M; Janzén D; Van Zuydam N; Hugerth A; Larsson A; Abrahmsén-Alami S; Abrahamsson B; Davies N; Bergström CAS
J Control Release; 2023 Jan; 353():792-801. PubMed ID: 36493948
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
